November 1, 2019 Comments (0) Blog, Current Investigations

Immune Pharma Files Chapter 11 Bankruptcy Protection

Immune Pharma Files Chapter 11 Bankruptcy Protection, featured by Top Securities Fraud Attorneys, The White Law Group

Immune Pharmaceuticals Securities Investigation

Have you suffered losses investing in Immune Pharmaceuticals? If so, the securities attorneys at The White Law Group may be able to help you by filing a FINRA Dispute Resolution claim against the brokerage firm that sold you the investment.

Immune Pharmaceuticals, a clinical-stage biopharmaceutical company, reportedly filed for bankruptcy protection on February 17, 2019, according to a press announcement.

The company was reportedly engaged in developing a treatment for a rare skin condition called bullous pemphigoid, but apparently exhausted its capital and was unable to raise more, according to an article in BioPharma Dive.

In April 2017, Immune reportedly cut its workforce to concentrate on its lead asset while also reportedly conducting a reverse stock split to boost its share price.

By the end of 2017, the company “openly acknowledged its limited liquidity, reporting only about $7 million in cash and equivalents,” according to BioPharma Dive.

The company reportedly announced its plans to file Chapter 11 in February after it had reportedly exhausted its funding sources and couldn’t advance its lead program to Phase 3 testing.

Recovery of Investment Losses

The problem with biopharmaceutical stocks such as Immune Pharmaceuticals is that they typically involve a high degree of risk. The research and development process for pharma companies often involves costly and lengthy clinical testing trials that yield specific data. If the expected data or end points are not met, the stock can drop drastically.

Without a strong understanding of the company and its basic operations, investors may be looking at serious losses.

The White Law Group is investigating the liability that FINRA registered brokerage firms may have for improperly recommending high-risk biopharma stocks, like Immune Pharmaceuticals to investors.

Broker dealers are required to perform adequate due diligence on any investment they recommend and to ensure that all recommendations are suitable for the investor. Firms that fail to do so, may be held responsible for any losses in a FINRA arbitration claim.

If you have concerns regarding investment losses in Immune Pharmaceuticals, please call the securities attorneys at The White Law Group for a free consultation at 888-637-5510.

The White Law Group, LLC is a national securities fraud, securities arbitration, investor protection, and securities regulation/compliance law firm with offices in Chicago, Illinois and Franklin, Tennessee.

For more information on The White Law Group and its representation of investors in FINRA arbitration claims, visit https://www.whitesecuritieslaw.com.

 

 

»

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.